Immune Checkpoint Patient Stratification: A Central Laboratory Perspective

Get in Touch

Our Locations

Immune Checkpoint Patient Stratification: A Central Laboratory Perspective

DIA China 2018 lecture

This presentation provides an overview of trends in immuno-oncology studies targeting PD-1 and PD-L1, and discusses recruitment for immune checkpoint inhibitor trials, and provides challenges and insights. This was presented by Q² Solutions at the DIA China 2018 conference.

Download this presentation to learn more.

Speaker:
Patrice Hugo, PhD, Chief Scientific Officer

Related Services & Solutions

Related Thought Leaders Insights

Scientific Poster

Robust performance of single-cell multiomic analysis (CITE-Seq) demonstrated across multiple locations, replicates, and donors on challenging cryopreserved PBMC and BMMC samples

Q² Solutions is the first and only service provider to achieve the exclusive certified service partnership for CITE-Seq scRNA-Seq with BioLegend. Describes CITE-Seq performance expectations for...

Brochure

Challenging Bioanalytical Work

If you’re looking for solutions to analytical challenges, you’ve come to the right place. Our highly trained scientists partner with you to provide a well-planned strategy, no matter where you are in...

Factsheet

CNS Biomarkers

Rules-Based Medicine, a Q² Solutions company, offers ultrasensitive immunoassays – including beta-amyloids, GFAP, NF-L, and pTaus – for the development of diagnostics and therapeutics for Alzheimer’s...